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Introduction: The quality of life of acromegalics is compromised. Treatment with the
“Think healthy and feel the difference” technique has been described as effective in
the improvement of the quality of life of these patients in the short term. However, its
effectiveness in the long term needs to be evaluated.
Objective: The purpose of this study was to evaluate whether the good results obtained
from the “Think healthy and feel the difference” technique in the short term persists in the
long term, after the end of the treatment.
Method: This is a non-randomized longitudinal study with 23 acromegalic divided into
two groups: an intervention group with 10 patients and a control group with 13 patients.
The intervention itself covered nine group sessions, organized weekly, using a technique
called “Think healthy and feel the difference.” The control group did not receive the
aforementioned treatment. The Short Form 36 Question Health Survey (SF-36) and the
Beck Depression Inventory were administered before the sessions began, at the end of
the nine therapy sessions and at the 9-month follow-up.
Results: At the end of the treatment, the results of the SF-36 showed improvement in
the mental health of the intervention group compared to the control group. The effects
of therapy were maintained at the 9 month follow-up.
Conclusion: Cognitive-behavioral therapy, applied in a group format, can improve the
quality of life of acromegalic patients in the short- and long-term.
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INTRODUCTION
In acromegaly, prolonged exposure to growth hormone (GH) and insulin-like growth factor
(IGF-1) is associated with worsening comorbidities and impairment in quality of life (1).
Biochemical dysregulation of the disease can reduce acromegalic life expectancy by up to 10 years
(1, 2), but, when the disease is controlled, mortality may reach parity with the normal population
(2). Despite this, biochemical control of acromegaly through currently available treatments—
transsphenoidal surgery, radiotherapy and pharmacotherapy—has been insuﬃcient to improve
quality of life (2–4).
In addition to clinical complications, orofacial changes and orthopedic comorbidities can also
impair the quality of both functional and social life (1). Acromegalics show a preoccupationwith the
performance of tasks involved in executive dysfunction syndrome, which may impair the execution
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of everyday tasks (5), as well as jeopardize the development of
eﬀective coping strategies (6). Receptors for GH and IGF-1 are
present in the central nervous system, especially in the limbic
system and frontal lobe. An excess of GH and IGF-1 results in
cognitive impairment may be irreversible, as in valvulopathy and
arthropathy (6).
Delay in diagnosis is related to social isolation, distortion
of body image, and depression, with consequent psychosocial
impairment (1, 7). The impairment in quality of life may also
be related to psychiatric comorbidities, such as anxiety, cognitive
impairment, and depression, more frequently than in other
somatic diseases (1, 8).
Therefore, quality of life impairment may be related to
psychopathology and not only to biochemical dysregulation
of the disease (3). Cognitive dysfunctions due to emotional
imbalance have been observed in acromegalics, especially in
executive functions and in memory (5, 9, 10). Lower activation of
areas of the brain strongly associated with cognitive functions—
the prefrontal and temporal cortex—has been observed as
well (5).
Considering the importance of psychopathology in
acromegaly (3), particularly, related to the supposed irreversible
eﬀect of excess GH on mood and behavior (1), acromegalics can
benefit from psychotherapeutic treatment (2, 8, 9). However,
no results on the eﬀects of psychotherapy on improvement of
quality of life in acromegalics had been published until recently,
despite being well-established for other chronic diseases (4).
In this context, cognitive-behavioral therapy (CBT) can be
applied to cases of acromegaly. Over the years, research involving
CBT has contributed to clinical practice, since improvements
in techniques favor its application in diﬀerent clinical contexts
(11). More than 300 research studies have applied CBT to various
diseases, as it is an eﬀective intervention with a low cost (12).
Initially, the cognitive model, proposed by Aaron Beck in
the 1960s, was based on the cognitive distortions present in
depression (13). Depressive content was characterized by low
self-esteem and guilt with a consequent desire for isolation (14).
In CBT, thought, emotion, and behavior are intertwined (14, 15).
The cognitive model has been adapted for various diseases.
In this model, schemas are sets of beliefs associated with
greater emotional imbalance (13, 16, 17). Due to facial changes
and growth of their hands and feet, (1), acromegalics can
present schemas of inadequacy, devaluation and failure. As
with acromegalics, depressed patients overestimate their defects,
failures, and problems, and tend to underestimate or ignore any
favorable traits, skills, or achievements (14).
The cognitive conceptualization of each case is facilitated by
Socratic questioning. The therapist formulates questions to help
the patient understand the eﬀects of emotions and thoughts
on behavior. Such questioning aims at developing new coping
perspectives from the learning process (18).
Abbreviations: BDI, beck depression inventory; CBT, cognitive-behavioral
therapy; CG, control group; GH, growth hormone; IG, intervention group; IGF,
insulin-like growth factor-1; MRI, magnetic resonance imaging; SF-36, quality of
life questionnaire.
Among several clinical applications, in social phobia, for
example, the patient feels threatened in social situations, thinking
“If I try to talk, I’ll look stupid”; as a result the patient avoids
social interaction (13). In acromegaly, because of their physical
appearance, the cognitive model may be similar, based on the
belief: “If I look horrible, everyone will stare and criticize me.”
Uncertainty, cost and benefit assessment, and perceived risk
precede the choice of a given behavior, and require some degree
of flexibility (19). Despite the importance of decisionmaking, not
much research has been carried out the influence of emotional
imbalance on choices (20). In the brain, activation of the
cingulate cortex and the amygdala is important because of their
role in emotional regulation, which is one of the main objectives
of CBT (21, 22).
In this context, the “Think healthy” technique was applied
in a group setting with the aim of improving the quality
of life of acromegalics (23). The technique is composed of
six stages and uses the figures of gray and green avocados
to represent problems and possible coping alternatives (23).
One of its fundamental principles is decision making toward
healthy behaviors, facilitated by the following thought: “Despite
the negative repercussions of acromegaly, what can I do that is
healthier toward thinking and behavior?”
In a previously published study, we showed that CBT, with the
“Think Healthy” technique, significantly improved the quality of
life of acromegalics; evaluated by the SF-36 in the areas of general
health (d′ =−0.264, p= 0.031) and mental health (d′ =−1.123,
p = 0.012). In the dimensions of physical and emotional aspects
there were no significant improvement, although four of the five
patients with floor eﬀects did improve (23).
The aim of the present study is to evaluate whether the initially
obtained results were still present after 9 months from the end of
the treatment. It also compares whether, after that period of time,
the treatment group shows any diﬀerence to the control group
that did not receive the treatment at the same time.
METHODS
This was a non-randomized longitudinal study performed on
acromegalics attending the neuroendocrinology outpatient clinic
of the University Hospital of Brasília in the period from
September 2015 to November 2016.
The following inclusion criteria were used: patients with
acromegaly in follow-up at the above-mentioned clinic, males
and females, aged between 18 and 75 years; intellectual capacity to
follow the intervention; and agreement to participate in the study.
The exclusion criterion was risk of suicide, evaluated according to
the response to item 9 of the BDI (24).
The meetings were held in a space that comfortably
accommodated the number of participants, arranged in a circle,
with the possibility of handling the material, taking notes and
completing exercises. The room was well lit, cool, and had
good privacy.
The clinical trial was registered in a public trial registry, and
the accession number is UTN—U 1111-1220-9846. The research
project was approved by the Research Ethics Committee (CEP) of
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the Faculty of Health Sciences of the University of Brasília—UnB.
A Free and Informed Consent form was read and signed by the
participants of the group.
Sample Composition and Evaluation Steps
One week before the start of group therapy, which was
considered the pre-intervention stage, the work proposal, the
dates scheduled for the meetings, and the content scheduled for
each session were provided. Information was collected about age,
gender, time, and activity of the disease, arterial hypertension,
diabetes, arthralgia, and type of acromegaly treatment—surgery,
radiotherapy and/or oral or injectable medication.
The disease was considered active when IGF-1 was above the
normal value for age and gender, even when using cabergoline,
octreotide, or pegvisomant; considered controlled when the use
of these drugs kept blood concentrations of IGF-1 within the
normal range; and considered cured when the concentrations of
this hormone were within the normal range without the use of
these drugs. Hypertensive participants were considered as those
with blood pressure equal to or >140 × 90 mmHg, or those
using anti-hypertensive drugs (25). A participant was considered
to have diabetes mellitus type 2 when glycemia was equal to or
higher than 125 mg/dL, or 2 h post oral glucose tolerance test
higher than 199 mg/dL or HbA1 levels equal to or higher 6.5%,
or if he/she was using hypoglycemic drugs (26).
The groups were selected according to convenience,
availability, and the choice of each participant. Patients of
the control group did not participate on this phase of the
research due to the distance of their homes or diﬃculties with
transportation. Despite the interest in participating, they did
not manage to do so due to the need to be at the ambulatory on
a weekly basis. Those who chose to participate in the therapy
sessions were considered as the intervention group (IG)—aged
between 42 and 69 years—and those who preferred not to
participate in this phase of the experiment were considered as
the control group (CG)—aged between 30 and 75 years. All
participants in the two groups responded to the evaluation
instruments before the treatment started.
The details of all steps of the treatment were clarified.
Acromegalics attended weekly, one and a half hour group
sessions that applied the technique “Think healthy and feel the
diﬀerence” (23, 27–30); for a total of 9 weeks. The IG was treated
in the 3 month period from September to November 2015.
In the post-intervention step, after the end of the nine sessions
of application of the technique, all IG and CG participants were
submitted to evaluations with the aim of analyzing the eﬀect of
CBT on the IG. The results were compared between groups.
For the follow-up phase, in August 2016, 9 months after
the end of the IG sessions, the IG and CG participants were
once again submitted to evaluations. Three participants in the
control group did not respond to the evaluation instruments. As
a result, the total number of participants dropped from 23 to
20 (Figure 1).
Evaluation Instruments
For acromegaly, AcroQol is the instrument used in 80% of studies
to evaluate quality of life. It consists of 22 questions, 11 of them
more directly related to physical alterations. Regarding the level
of cognition, seven of the questions are conditional beliefs with
emotional dysregulation of moderate intensity, as for example,
item 8: “I feel rejected by people because of my illness.” Four
of them are core beliefs with greater emotional dysregulation,
for example, item 4: “I look awful in photographs.” Because
of the risk of intense imbalance emotion, AcroQol questions
were used only in the seventh session for the participants to
identify their cognitive distortions, restructure them and build
healthier behaviors.
Because of this, two self-administered evaluation instruments
were answered by the participants of the two groups in the three
stages of the present study: pre-intervention, post-intervention,
and follow-up.
Quality of Life Questionnaire (SF-36)
The Short Form 36 Question Health Survey (SF-36) was used
to evaluate quality of life (31). This is a multidimensional
questionnaire, composed of 36 items, subdivided into eight
sections with their respective questions: physical functional (item
03); role-physical (item 04); bodily pain (items 07 and 08); general
health (items 01 and 11); vitality (options a, e, g, and i of item 09);
social functioning (items 06 and 10); role-emotional (item 05),
andmental health (options b, c, d, f, and h of item 09). In addition
to the eight sections, item 02 is not part of the calculation of any
section, being used only to evaluate how much the individual is
better or worse compared to a year ago. It presents a final score
of 0 (zero) to 100 (hundred), in which zero shows the worst state
and 100 the best state (31).
Beck Depression Inventory (BDI)
The Beck Depression Inventory (BDI) was used to evaluate signs
of depression (24). The following levels were considered for this
scale, as they are for psychiatric patients: minimal: 0 to 11; mild:
12 to 19; moderate: 20 to 35; serious: 36 to 63. A score of 18 to 19
indicates likelihood of depression (24).
Intervention Protocol
The “Think healthy and feel the diﬀerence” protocol (23, 27–
30), adapted for patients with acromegaly, was applied in a
group setting and all participants received printed material.
The technique is available to download as an application for
mobile devices at the Apple Store and Google Play, under
the name “Think Healthy,” with versions in Portuguese and
English. Patients allowed the researcher to record the sessions for
later transcription.
A small, plastic, coping card, measuring 10 × 6 cm, with
an illustration of the avocados, was delivered to encourage
the practice of the techniques and healthy decision making in
moments of emotional imbalance.
In each session, specific topics were covered. The content
of the sessions was presented as follows: (1) basic concepts
of CBT and practical examples of the relationship between
unhealthy and healthy levels of cognition with emotion and
associated behaviors; (2) emotional regulation; (3) increase
self-esteem and self-confidence, and supply of a brain-shaped
piggy bank (identification and valuation of personal qualities
Frontiers in Endocrinology | www.frontiersin.org 3 June 2019 | Volume 10 | Article 380
Kunzler et al. Cognitive-Behavioral Therapy on Acromegaly
FIGURE 1 | Sample composition and evaluation steps.
and achievements); (4) “Think healthy and feel the diﬀerence”
technique—guidelines for completing the six steps adapted
for the practice of physical activity; (5) the technique for
approaching anger, assertiveness training, and the coping card;
(6) the technique for approaching fear; (7) the technique adapted
for shame about one’s physical appearance in acromegaly; (8)
clarifications on acromegaly, and (9) a summary of the topics
covered in the sessions.
To consolidate knowledge and to assist in the practice of
cognitive and behavioral skills between the therapy sessions, a
therapy notepad and block of coping cards were provided (29).
Data Analysis
To verify the equivalence of profiles of both the control and the
intervention groups, we performed the non-parametric Mann-
Whitney U test for the scalar variables (32). For the categorical
variables, Chi-square or Fisher’s tests were performed (32).
To control the impact of non-randomization on the
distribution in the groups, we performed covariance analysis
(ANCOVA) to compare the SF-36 and BDI measurements in
the post intervention period. The baseline means were used as
covariates; thus, the groups were equalized by their baseline in
the post-intervention comparison (33, 34).
In order to verify whether the clinical eﬀect was sustained 9
months after the intervention, the same procedure to compare
the measures post-intervention was done; however, to it was
added the measures of the post-intervention as a covariant, as
well as the baseline. Moreover, the comparison between the
intervention and the control groups was made. Student’s t-Test,
paired, was used when comparing the measures of the baseline
and of the post-intervention, and whether the clinical eﬀect
was sustained.
To interpret the size of the eﬀects, Cohen’s criterion was
adopted: small (d′ < 0.3), moderate (0.3 ≤ d′ < 0.5), or large (d′
≥ 0.5) (35). In all analyses, statistical significance was considered
to be p < 0.05. In order to determine if the sample size was
adequate for the eﬀect size, thus avoiding a type II error, post-
hoc analysis was made using the G∗POWER 3.1 software, where
the acceptable statistical power found was β= 0.80 (36, 37).
RESULTS
Sixty-two acromegalics were selected from the endocrinology
clinic of the University Hospital of Brasília. Thirty-nine of them
did not agree to participate in the study, mainly because they
could not attend the study site on a weekly basis. Thus, the sample
consisted of 23 patients. There were 15 women (65.2%). Ages
ranged from 30 to 75 years (mean = 52.78 ± 12.86 years, CV
= 0.24, n = 23), from 42 to 69 years in the intervention group,
and from 30 to 75 years in the control group. The mean time
since disease diagnosis was 11.60 ± 7.14 years (CV = 0.62, n
= 23). The time lag between the diagnosis and the beginning
of the treatment ranged from 0.17 to 18 years (mean = 6.37
± 4.94 years, CV = 0.78, n = 23). Regarding the stages of
the disease, four (17.40%) were classified as cured, in 10 it was
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TABLE 1 | Comparison between the control group and the intervention group in relation to age, gender, the clinical and laboratory aspects of the disease, and the study
variables in the baseline (n = 23).
Control (n = 13) Intervention (n = 10) p-value*
Median (Q1–Q3) Median (Q1–Q3)
Age (years) 55.00 (50.0–62.0) 46.00 (37.8–58.3) 0.335
Time since diagnosis (years) 11.00 (4.8–19.3) 12.00 (8.75–16.5) 0.926
Delay in diagnosis (months) 48.00 (24.0–108.0) 84.00 (66.0–120.0) 0.532
Largest diameter in MRI (mm) 20.00 (17.0–27.0) 12.00 (11.3–49.5) 0.815
ULNR IGF-1 (%) 117.45 (109.8- 121.3) 118.70 (103.38–245.88) 0.664
f(%) f(%) p-value†
Gender
Male 6 (46.15) 1 (10.00) 0.074
Female 7 (53.85) 9 (90.10)
Disease activity
Active 6 (46.15) 3 (30.00) 0.734
Controlled 5 (38.46) 5 (5.00)
Cured 2 (15.38) 2 (2.00)
Underwent surgery
Yes 12 (92.31) 8 (80.00) 0.560
No 1 (7.69) 2 (20.00)
Using acromegaly medication
Yes 11 (84.62) 10 (100.00) 0.486
No 2 (15.38) 0 (0.0)
Underwent radiotherapy
Yes 3 (23.08) 4 (40.00) 0.650
No 10 (76.92) 6 (60.00)
Symptoms of depression (BDI)
Minimal 7 (53.85) 4 (40.00) 0.805
Mild 3 (23.08) 3 (30.00)
Moderate 3 (23.08) 3 (30.00)
Study variables Mean Standard deviation Mean Standard deviation p-value‡
Physical functional 70.00 26.06 58.50 26.67 0.311
Role-physical 50.00 36.80 32.50 39.18 0.284
Bodily pain 66.67 24.00 38.89 12.00 0.002
General health 53.08 15.07 46.00 21.58 0.364
Vitality 58.85 14.74 55.00 10.00 0.487
Social functioning 62.50 27.95 67.50 14.67 0.614
Role-emotional 56.41 45.92 43.33 49.81 0.521
Mental health 67.08 20.73 62.00 15.23 0.523
Beck depression inventory 12.23 9.57 13.30 9.03 0.788
Q1, 1◦ Quartile; Q3, 3◦ Quartile; *Non-parametric Mann-Whitney test; †Chi-squared test; ‡t-test for repeated measurements.
under control (43.50%), and in nine it was active (39.10%). The
MRI assessment of the tumor showed the mean of the largest
diameter was 23.36 ± 16.49mm (CV = 0.71; n = 22). The
percentage of IGF-1 levels (ULNR IGF-1) ranged from 30.30 to
384.30 (mean = 144.33 ± 85.00, CV = 0.59, n = 23). As for
the treatment strategies, 20 (87%) underwent surgery, 21 (91.3%)
used medication, and seven (30.40%) underwent radiotherapy.
Regarding the level of depression, 11 (47.8%) presented minimal
scores according to the BDI, six (26.1%) had mild scores, and six
(26.1%) had moderate scores.
As shown on Table 1, there was no significant diﬀerence
between all the variables studied: age, time since diagnosis, delay
in diagnosis, largest tumor diameter in MRI, IGF-1 ULNR %,
gender, disease activity, underwent therapies, and symptoms of
depression. Among the variables in the study, only bodily pain
presented significant diﬀerences (p = 0.002), where the control
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TABLE 2 | Effect of the treatment on the intervention group compared to the control group (no treatment) in relation to the quality of life questionnaire SF-36 and the Beck
Depression Inventory (n = 23).
Control–post (n = 13) Intervention–post (n = 10) p-value§
Mean Standard deviation d′ post × pre Mean Standard deviation d’ post × pre
Physical functional 66.92 26.34 −0.117 52.50 27.21 −0.223 0.481
Role-physical 59.62 47.37 0.228 65.00 42.82 0.793 0.252
Bodily pain 65.81 25.44 −0.035 50.00 17.57 0.752 0.705
General health 57.69 18.44 0.275
†
51.50 20.15 0.264† 0.984
Vitality 66.15 9.61 0.600
†
54.50 14.03 −0.042 0.041
Social functioning 77.88 17.04 0.684 76.25 18.11 0.534 0.571
Role-emotional 53.85 48.19 −0.155 76.67 35.31 −0.243 0.740
Mental health 68.92 15.68 0.101 76.80 11.12 1.123* 0.025
Beck depression inventory 7.54 7.69 −0.544 12.50 8.49 −0.091 0.139
d′- d′ of Cohen; *t-test for repeated measurements p<0.01 ; †t-test for repeated measurements p < 0.05; §ANCOVA; Post: Intervention x Control, Covariant: Baseline (SF36 and BDI).
group had a higher score (mean = 66.67 ± 24.00) compared to
the intervention one (mean= 38.89± 12.00).
The results of the eﬀect of the treatment on the intervention
group compared to the control one (patients who did not
receive treatment) are presented in Table 2. Concerning the SF-
36 sections, Vitality was higher in the control group (mean =
66.15 ± 9.61; p = 0.041; β > 0.80). However, Mental Health
(mean = 76.80 ± 11.12) was higher in the intervention group
when compared to the control group (mean = 68.92 ± 15.68;
p = 0.025; β > 0.80). There were no significant diﬀerences
between both groups in all the other sections. Regarding
the BDI, no significant diﬀerences were observed between
the groups either.
When comparing the baseline to the post-intervention, there
was a significant increase in the score of General Health both in
the control group (D′ = 0.280; P = 0.038; B > 0.80) and in the
intervention one (D′ = 0.26; P = 0.024). Regarding the Vitality
section, there was a significant increase only in the control group
(D′ = 0.60; P= 0.022; β> 0.80). The score for Mental Health has
a significant increase (P = 0.008), the greatest eﬀect found (D′
= 1.123; β > 0.80). There were no significant diﬀerences in the
other sections nor in the BDI evaluation.
Table 3 presents the adjustments measures for the ANCOVA
models of the eﬀect of the treatment in the intervention group
compared to the control group, which did not receive the
treatment, in the post-intervention. Concerning the SF-36, the
sections were well-adjusted to the model, except for the Vitality
variable (R2 = 0.176).
Nine months after the end of the intervention, patients of
both groups were again evaluated using SF-36 and BDI. Only
the Mental Health section sustained a significant diﬀerence (p
= 0.033) when comparing the control group (mean = 65.60 ±
15.91) to the intervention group (mean = 74.80 ± 21.25), in
which case the intervention one had higher score (β> 0.80). The
patients during the 9 months before the final evaluation had no
changes in their disease stage.
The comparison between the post-intervention and the 9
month follow-up is presented in Table 4. The t-test for repeated
measurements did not show significant diﬀerence either in the
TABLE 3 | Adjustment measures for the ANCOVA models (n = 23) when
comparing the control group (no treatment) to the intervention group in the








Physical functional 62.88 57.75 0.647 65.00
Role-physical 53.89 72.44 0.334* 42.39
Bodily pain 57.37 60.98 0.339* 54.59
General health 55.00 54.94 0.639* 50.00
Vitality 65.81 54.95 0.176 57.17
Social functioning 78.77 75.10 0.225* 64.67
Role-emotional 50.99 80.38 0.292* 50.72
Mental health 67.77 78.29 0.477* 64.87
Beck depression
inventory
7.76 12.21 0.311* 12.70
R², Model adjustment; *p < 0.001.
control group or the intervention group in any of the SF-36
sections or BDI.
Table 5 presents the adjustment measures for the ANCOVA
models when comparing the follow-up between the groups.
Regarding the SF-36 instrument, only the Bodily Pain section (R2
= 0.156), General Health Perception (R2 = 0.141) and Mental
Health (R2 = 0.351) were well-adjusted to the model.
DISCUSSION
The results showed that the application of the “Think Healthy”
technique, for 9 weeks, resulted in an improvement in the
quality of life in the intervention group when compared to the
control group. This confirms the previous observation that the
technique is useful in psychological support of acromegalics. (23).
Furthermore, the present study supplements that the eﬀect was
maintained at a 9 month follow-up, which suggests stability in
the eﬀects produced by the treatment.
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TABLE 4 | Comparisons of follow up between the control and intervention groups in relation to the quality of life questionnaire SF-36 and the Beck Depression Inventory
(n = 20).
Control–follow-up (n = 10) Intervention–follow-up (n = 10) p-value*
Mean Standard deviation d′ Mean Standard deviation d′
follow-up x post follow-up x post
Physical functional 69.50 24.43 0.041 50.00 27.59 −0.091 0.364
Role-physical 58.33 43.30 0.130 50.00 45.64 0.413 0.989
Bodily pain 56.67 20.59 −0.448 51.11 24.68 0.053 0.852
General health 54.00 16.47 −0.215 47.00 20.58 −0.221 0.255
Vitality 59.50 12.12 −0.562 50.00 14.14 −0.319 0.395
Social functioning 73.75 18.11 −0.296 65.00 27.51 −0.493 0.308
Role–emotional 55.56 47.14 −0.155 53.33 50.18 −0.546 0.970
Mental health 65.60 15.91 −0.133 74.80 21.25 −0.124 0.033
Beck depression inventory 11.40 12.02 0.424 10.60 6.24 −0.258 0.465
d′- d′ of Cohen; *ANCOVA, Post: Intervention x Control, Covariant: Baseline and Post (SF36 and BDI)
TABLE 5 | Adjustment measures for the ANCOVA models (n = 20) when comparing the control group (no treatment) and the intervention one, during the follow-up, in
relation to the quality of life questionnaire SF-36 and the Beck Depression Inventory.
Control (n = 10) Intervention (n = 10) R² Base level standardization
Baseline Post
Physical Functional 64.215 55.285 0.488 63.75 60.50
Role-Physical 53.792 54.087 0.018 42.11 65.79
Bodily Pain 55.152 52.626 0.156* 52.22 58.33
General Health 55.645 45.355 0.141* 51.00 54.75
Vitality 57.384 52.116 0.221 57.25 60.25
Social Functioning 75.03 63.72 0.017 63.75 77.50
Role-Emotional 53.908 54.816 0.059 52.63 70.13
Mental Health 60.997 79.403 0.351* 63.60 72.20
Beck Depression Inventory 12.53 9.47 0.149 12.50 9.80
R², Model adjustment; *p < 0.01.
The strategy used here—nine sessions of group therapy—
should be eﬀective, since in groups with obsessive-compulsive
disorder, a program of seven sessions was as eﬀective as the same
program conducted over 12 sessions (38).
Thus, the good long-term results, described here, of the
use of CBT in improving quality of life in acromegalics fills a
gap in the management of these patients. This is because, the
psychotherapeutic approach has been described as important in
other chronic diseases, but not in acromegaly (4).
Regarding the results achieved in the SF-36, in the
intervention group, the mental health dimension had a
significant increase, showing the greatest eﬀect with the
treatment (Table 4). In both groups there was an improvement
in general health, which could be explained by the fact
that all participants of the study where treated on the same
neuroendocrinology outpatient clinic of the University Hospital
of Brasília.
In the control group, the diﬀerence in the vitality variable
should be interpreted with caution, since it did not present a
good fit for the model (R2 = 0.176) (Table 3). This result shows
the need of having other studies as well to try and explain this
finding. What could have happened is that the IG participants
have learned to observe themselves while the CG participants
stayed lenient to their evaluation. The other dimensions did not
show significant diﬀerences, although some presented moderate
and large eﬀects, and fitted the model well.
The improvement in quality of life after treatment and
the fact that it was maintained after a 9 month follow-up
may have been facilitated by the characteristics of CBT. The
intervention stimulates visual memory, because it uses visual,
verbal, andwritten support. Tasks based onCBT require planning
and execution—executive function—and can be considered
cognitive training. Socratic questioning—characteristic of the
systematization of the technique in its six stages—favors the
learning and active participation of patients in their treatment
process (18).
In terms of outcome and maintenance of the achieved
improvement, the results of this research are similar to those
obtained in other studies on other diseases. Improvements
achieved in obsessive-compulsive symptoms were maintained
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in evaluations after a 1-year (38) and a 2-year follow-up (39).
Positive results were also achieved and maintained in follow-ups
for other disorders: anxiety in young people (40), obesity with
binge eating (41), general anxiety, (42) psychiatric disorders in
comorbidity (43), compulsive shopping (44), social anxiety (17),
and body dysmorphic disorder in adolescents (45).
The results described here, using CBT to improve quality
of life, are of particular importance because it is still uncertain
whether the control of the disease is associated with some
gain in this parameter. For example, with biochemical control
of acromegaly, a study with a longer duration of follow-up
(mean follow-up 5.7 ± 0.6 years) did not show improvement
in quality of life when compared to the control group (46).
These authors emphasized that addressing physical and psycho-
social comorbidities is as important as the biochemical control
of the disease (46). This study (45) evaluated the quality
of life of 106 surgically treated patients, 3 and 12 months
after the surgical intervention. Regarding the SF-36, there was
improvement in all dimensions, but it was not statistically
significant (47).
On the other hand, a study that used the SF-36 to evaluate the
quality of life of 41 acromegalics before surgery, after surgery,
and at a 1-year follow-up, showed a statistically significant
improvement in the following dimensions: role-physical, general
health, social functioning, and mental health (7). These results
were similar to those described in this study for the domains of
general health and mental health.
The short-lasting treatment and the possibility of recurrence
at the end of the treatment are of real concern; however, in the
present study the results were maintained at a 9-month follow-
up. Some participants reported the benefits of the group format
for learning coping strategies. This may be because learning and
living experiences, such as psychotherapy, can induce epigenetic
changes in brain circuits, similar to the eﬀect of medication (48).
When pharmacology is combined with psychotherapy, due to
therapeutic synergy, the result tends to be greater than the sum
of the two treatments (1+ 1= 3) (48).
In the present study, the BDI score levels of the psychiatric
patients (i.e., minimum, mild, moderate, and severe) were used
because of the lack of a cutoﬀ point for patients with acromegaly.
In the pre-intervention assessment, three participants showed
an indication of moderate depression, three showed mild
depression, and four showed minimal depression. No participant
in the present study showed an indication of severe depression.
The lowest depression score possible (i.e., zero) was found in only
one study participant. In that case, no improvement was possible,
which is considered a floor eﬀect. In addition, the decrease in BDI
score was not significant.
Even though there is no gender diﬀerence between both
groups, there was a tendency, which may point to a limitation
in the generalization of the study. For this reason, the authors
suggest that new gender stratification studies be carried in
the future.
A limitation of the present study is the small case-by-case
analysis; however, acromegaly is a rare disease. In addition, we
used a convenience sample, in which the patients presented
for the treatment, rather than a random sample. However, the
psychotherapeutic approach was showed to reduce the suﬀering
and improve the quality of life for acromegalics, with good
short- and long-term results. The results achieved by this
study reinforce the importance of more research on the use of
cognitive-behavioral techniques in diﬀerent clinical contexts.
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